CL2013001231A1 -
Anti-il-23p19 antibody or its antigen binding fragment; polynucleotide that encodes it; pharmaceutical composition that includes it; and its use to treat various diseases.
- Google Patents
Anti-il-23p19 antibody or its antigen binding fragment; polynucleotide that encodes it; pharmaceutical composition that includes it; and its use to treat various diseases.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=52014812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001231(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim IntfiledCriticalBoehringer Ingelheim Int
Publication of CL2013001231A1publicationCriticalpatent/CL2013001231A1/en
CL2013001231A2010-11-042013-05-03
Anti-il-23p19 antibody or its antigen binding fragment; polynucleotide that encodes it; pharmaceutical composition that includes it; and its use to treat various diseases.
CL2013001231A1
(en)
Anti-il-23p19 antibody or its antigen binding fragment; polynucleotide that encodes it; pharmaceutical composition that includes it; and its use to treat various diseases.
Antibody or antigen binding fragment thereof that binds to human pcsk9; pharmaceutical composition that includes it; and its use to treat hyperlipidemia or hypercholesterolemia.
Isolated antibody or fragment that binds to an inactive state of a her receptor; pharmaceutical composition that includes it; use of the antibody to treat cancer.
Isolated antibody or antigen binding fragment thereof that specifically binds to human cd48 and blocks the interaction between human cd48 and a cd48 receptor; pharmaceutical composition that includes it; And its use.
Antibody or antigen-binding fragment thereof that binds to the human c5a peptide of the complement system; pharmaceutical composition comprising it; and its use for the treatment of acute inflammatory diseases.
Isolated bivalent antibody or bivalent fragment thereof, which acts on lrp6 enhancing a wnt signal by grouping one or more lrp6 receptors in the presence of a lrp6 binding protein; nucleic acid encoding it; vector comprising said nucleic acid; pharmaceutical composition comprising a multivalent anti-lrp6 antibody; and its use to treat cancer.
Chimeric or humanized antibody or fragment thereof that specifically bind to at least one epitope in the beta-amyloid protein; nucleic acid molecule that encodes it; composition that includes it; and its use to treat diseases associated with the formation of amyloid plaques.
Multispecific antibody comprising a binding domain to the antigen that binds to egfr and her3; nucleic acid encoding it; host cell; Method of production; immunoconjugate; pharmaceutical formulation comprising the antibody; and its use to treat cancer.
Humanized anti-cd40 antibody; polynucleotide encoding it; pharmaceutical composition comprising said antibody; and its use to block an immune response mediated by human cd40.
pharmaceutical composition for treating and / or preventing cancer, antibody, pharmaceutical combination and method for treating and / or preventing cancer
Monoclonal antibody that binds to beta amyloid peptide n3pglu or antigen binding fragment thereof; pharmaceutical composition that includes it; and its use to treat Alzheimer's disease.
Antibodies from a single dab variable domain that bind to human cd40; nucleic acid encoding said antibody; vector and host cell that comprise it; pharmaceutical composition; use of said antibodies to treat immune disease.
Antibody that specifically binds to the fibroblastic activation protein (fap); polynucleotide that encodes it; vector; host cell; Method of production; pharmaceutical formulation that includes it; and its use to treat cancer.
Bispecific antibody that specifically binds to human erbb-3 and human c-met proteins; nucleic acid encoding it; pharmaceutical composition that includes it; and its use to treat cancer